中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2014年
31期
117-119
,共3页
王娴%熊盾%杨波%李海燕%李秋宇
王嫻%熊盾%楊波%李海燕%李鞦宇
왕한%웅순%양파%리해연%리추우
盐酸羟考酮控释片%加巴喷丁%癌痛%神经病理性疼痛%止痛
鹽痠羥攷酮控釋片%加巴噴丁%癌痛%神經病理性疼痛%止痛
염산간고동공석편%가파분정%암통%신경병이성동통%지통
Oxycodone ketone controlled release tablets%Gabapentin%Cancerous pain%Meuropathic pain%Pain relieving
目的:观察盐酸羟考酮控释片联合加巴喷丁治疗癌症神经病理性疼痛的疗效及不良反应。方法:单药组盐酸羟考酮控释20 mg/片,口服每12 h 1次。联合组盐酸羟考酮控释20 mg/片,口服每12 h 1次;加巴喷丁胶囊300 mg/片,口服每12 h 1次。治疗2周后评价疗效。结果:单药组和联合组总有效率分别为70.83%(17/24)、91.67%(22/24),比较差异有统计学意义(P<0.05)。患者不良反应主要是便秘,恶心呕吐。结论:盐酸羟考酮控释片联合加巴喷丁治疗癌症神经病理性疼痛明显优于单药盐酸羟考酮控释片方案,两种药物联合使用相互取长补短,止痛效果好,安全有效并且不良反应无明显增加,值得进一步深入研究和临床推广使用。
目的:觀察鹽痠羥攷酮控釋片聯閤加巴噴丁治療癌癥神經病理性疼痛的療效及不良反應。方法:單藥組鹽痠羥攷酮控釋20 mg/片,口服每12 h 1次。聯閤組鹽痠羥攷酮控釋20 mg/片,口服每12 h 1次;加巴噴丁膠囊300 mg/片,口服每12 h 1次。治療2週後評價療效。結果:單藥組和聯閤組總有效率分彆為70.83%(17/24)、91.67%(22/24),比較差異有統計學意義(P<0.05)。患者不良反應主要是便祕,噁心嘔吐。結論:鹽痠羥攷酮控釋片聯閤加巴噴丁治療癌癥神經病理性疼痛明顯優于單藥鹽痠羥攷酮控釋片方案,兩種藥物聯閤使用相互取長補短,止痛效果好,安全有效併且不良反應無明顯增加,值得進一步深入研究和臨床推廣使用。
목적:관찰염산간고동공석편연합가파분정치료암증신경병이성동통적료효급불량반응。방법:단약조염산간고동공석20 mg/편,구복매12 h 1차。연합조염산간고동공석20 mg/편,구복매12 h 1차;가파분정효낭300 mg/편,구복매12 h 1차。치료2주후평개료효。결과:단약조화연합조총유효솔분별위70.83%(17/24)、91.67%(22/24),비교차이유통계학의의(P<0.05)。환자불량반응주요시편비,악심구토。결론:염산간고동공석편연합가파분정치료암증신경병이성동통명현우우단약염산간고동공석편방안,량충약물연합사용상호취장보단,지통효과호,안전유효병차불량반응무명현증가,치득진일보심입연구화림상추엄사용。
Objective:To observe the efficiency and side-effects of combined function of both oxycodone ketone controlled release tablets and gabapentin in the treatment of cancerous neuropathic pain. Method:Patients would be arranged in three groups:oxycodone ketone controlled release tablet monotherapy group(20 mg,Q12h,po). Combined therapy group(oxycodone ketone controlled release tablet:20 mg,Q12h,po;gabapentin:300 mg,Q12h,po). After 2 weeks treatment,the efficacy of both groups would be assessed. Result:The efficacy of monotherapy group was 70.83%(17/24)while that was 91.67%(22/24)in combined therapy group. There was significant difference in efficacy between the two groups(P<0.05). Side-effects as constipation,nausea and vomiting could be observed. Conclusion:Combined therapy of both oxycodone ketone controlled release tablets and gabapentin is significantly prior to monotherapy in the treatment of cancerous neuropathic pain. Combined therapy is feasible and can make the best of both medicine. It is worth further studying and widely clinical using.